Institut für Chemie und Bioanalytik

Dauerhafte URI für die Sammlunghttps://irf.fhnw.ch/handle/11654/24

Listen

Filter

1993 - 19942

Einstellungen

Enddatum: 1999Institut: search.filters.institut.Institut für Chemie und Bioanalytik

Ergebnisse nach Hochschule und Institut

Gerade angezeigt 1 - 2 von 2
  • Vorschaubild
    Publikation
    Dynemicin analogs: Syntheses, methods of preparation and use
    (United States Patent and Trademark Office, 04.01.1994) Smith, Adrian L.; Hwang, Chan-Kou; Wendeborn, Sebastian; Nicolaou, Kyriacos C.; Schreiner, Erwin P.; Stahl, Wilhelm; Dai, Wei-Min; Maligres, Peter E.; Suzuki, Toshio
    A fused ring system compound is disclosed that contains an epoxide group on one side or the fused rings and an enediyne macrocyclic ring on the other side of the fused rings. The compounds have DNA-cleaving, antimicrobial and tumor growth-inhibiting properties. Chimeric compounds having the fused ring system compound as an aglycone bounded to (i) a sugar moiety as the ogligosaccharide portion or(ii) a monoclonal antibody or antibody combining site portion thereof that immunoreacts with target tumor cells are also disclosed. Compositions containing a compound or a chimer are disclosed, as are methods or preparing a compound.
    12 - Patent
  • Vorschaubild
    Publikation
    Enantiomeric dynemicin analogs, preparation and use thereof
    (World Intellectual Property Organization, 25.11.1993) Smith, Adrian L.; Wendeborn, Sebastian; Nicolaou, Kyriacos; Schreiner, Erwin P.; Dai, Wei-Min; Susuki, Toshio
    An enantiomer of a fused ring system compound is disclosed that contains an epoxide group on one side of the fused rings and an enediyne macrocyclic ring on the other side of the fused rings. The enantiomeric compounds have DNA-cleaving, antimicrobial and tumor growth-inhibiting properties that are enhanced over their racemates. Chimeric compounds having the enantiomeric fused ring system compound as an aglycone bonded to (i) a sugar moiety as the oligosaccharide portion or (ii) a monoclonal antibody or antibody combining site portion thereof that immunoreacts with target tumor cells are also disclosed. Compositions containing an enatiomeric compound or an enantiomeric chimer are disclosed, as are methods of preparing an enantiomeric compound.
    12 - Patent